CORE--RADIOPHARMACY

核心B(放射性药学)的主要目标是为 项目1，人文科学。~(90)Y放射性标记嵌合体T84.66抗 CEA抗体将用于I期和II期临床试验 希望之城国家医疗中心的结肠癌和乳腺癌患者 中心。铟-111放射性标记嵌合T84.66抗体将用于 用于剂量学目的。碘-1`23标记嵌合T84.66片段 将用于第一阶段成像研究。放射性药房将支持 项目1，通过提供专业知识和设施来准备放射性标记 并为这些试剂提供质量控制。一项协议 用于大规模制备In-111、Y-90和I-123标记的单抗 抗体目前是活跃的。作为其核心活动的一部分， 放射性药物也支持单抗的偶联。 将在临床试验中使用的构造。 核心B的次要目标是为临床提供标签 开发新的构造物和络合物。通过这种方式，核心 支持项目2(生物工程抗体)和项目3(抗体 络合物和共轭)。生物化学和放射稳定性 将被确定为这些抗体制剂，前提是 提交IND申请的信息。

The primary objective of Core B (Radiopharmacy) is to provide support to Project 1, Human Studies. Yttrium-90 radiolabeled chimeric T84.66 anti- CEA antibody will be used in Phase I and Phase II clinical trials for colon and breast cancer patients at the City of Hope National Medical Center. Indium-111 radiolabeled chimeric T84.66 antibody will be used for dosimetry purposes. iodine-1`23 rabiolabeled chimeric T84.66 fragments will be used for Phase I imaging studies. The radiopharmacy will support Project 1 by providing expertise and facilities to prepare radiolabeled antibodies and to provide quality control for these reagents. A protocol for large-scale preparation of In-111, Y-90 and I-123 labeled monoclonal antibodies is currently active. As part of its core activity the Radiopharmacy also supports the conjugation of the monoclonal antibody constructs to be used in the clinical trials. The secondary objective of Core B is to provide labeling for clinical development of novel constructs and chelates. In this way, the Core supports project 2 (Bioengineered Antibodies) and Project 3 (Antibody Chelates and Conjugates). The biochemical and radiological stabilities will be determined for these antibody preparations, providing this information for the filing of IND applications.